Nephrogenex: Jefferies Global Healthcare Conference (Nephrogenex) - Jun 8, 2014 - Anticipated method of use (patient population) patent expiry in US in September 2028; Anticipated manufacturing patent expiry in US in September 2028; Anticipated NCE exclusivity in US until 2033; Anticipated method of use (patient population) patent expiry in Europe in June 2024; Anticipated manufacturing patent expiry in EU in June 2024; Anticipated NCE exclusivity patent expiry in EU in 2034; Anticipated method of use (patient population) patent expiry in Canada in June 2024; Anticipated manufacturing patent expiry in Canada in June 2024; Anticipated NCE exclusivity patent expiry in Canada in 2032
Anticipated patent expiry • Diabetic Nephropathy • Renal Disease
|